Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aiqikang capsules (艾奇康胶囊) is a traditional Chinese medicine (TCM) formulation developed for the treatment and management of HIV infection, particularly in patients with a Qi deficiency and blood stasis constitution. The formulation is composed of several herbal ingredients, including processed *Aconitum carmichaelii* (制附子), *Scutellaria baicalensis* (黄芩), *Angelica sinensis* (当归), *Piperis Albi Fructus* (白胡椒), *Fraxinus chinensis* (秦皮), *Galla chinensis* (五倍子), *Borneolum syntheticum* (冰片), and *Glycyrrhiza uralensis* (甘草). It has been evaluated in clinical trials in China, including studies sponsored by the First Affiliated Hospital of Henan College of TCM, to assess its efficacy in delaying progression to AIDS, reducing AIDS incidence, and improving immunologic and virologic markers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Aiqikang capsules.